<DOC>
	<DOCNO>NCT00468091</DOCNO>
	<brief_summary>The purpose study human define effect endogenous hormone GLP-1 gastroduodenal motility endocrine pancreatic secretion use specific GLP-1 receptor antagonist exendin ( 9-39 ) . To elucidate possible cholinergic pathway , combine exendin ( 9-39 ) muscarinergic antagonist atropine .</brief_summary>
	<brief_title>Effects Exendin ( 9-39 ) Gastroduodenal Motility</brief_title>
	<detailed_description>Following meal , gut-produced incretin hormone glucagon-like peptide-1 ( GLP-1 ) glucose-dependent insulinotropic polypeptide ( GIP ) release circulation . GLP-1 GIP , two dominant incretin hormone , part natural endogenous system involve maintain glucose homeostasis . In presence normal elevate , low , glucose concentration , GLP-1 GIP increase insulin secretion pancreatic islet beta-cells . GLP-1 also lower glucagon secretion pancreatic alpha-cells delay nutrient delivery stomach inhibit gastric emptying . These combined effect improve glucose tolerance provide rationale therapeutic potential GLP-1 analogue treatment diabetes mellitus . A dominant gastrointestinal action synthetic GLP-1 inhibition gastroduodenal stimulation pyloric motility , result delay gastric empty decreased glycemic excursion . Postprandial glucose fluctuation demonstrate important determinant glycemic control assess A1C . Moreover , emerge evidence show strong link transient postprandial hyperglycemia microvascular macrovascular complication diabetes mellitus . Deceleration gastric emptying consider mechanism lower postprandial glycemia patient diabetes mellitus . It part pharmacodynamic profile new antidiabetic incretinomimetica . In contrast , inhibition enzyme dipeptidylpeptidase 4 ( DPP-4 ) responsible rapid degradation GLP-1 fail show effect gastric empty human although plasma GLP-1 increase twofold . Most understanding effect GLP-1 base upon study employ synthetic GLP-1 whereas little know endogenously release GLP-1 . Using specific GLP-1 receptor antagonist exendin ( 9-39 ) able show endogenous GLP-1 act incretin hormone human . Moreover , inhibition antroduodenal stimulation pyloric motility duodenal glucose load reverse GLP-1 receptor antagonist . In order completely evaluate effect GLP-1 enterogastrone , present study examines effect exendin ( 9-39 ) antropyloroduodenal proximal gastric motility physiological meal . As cholinergic pathway think involved inhibitory action GLP-1 combine GLP-1 receptor antagonist muscarinergic antagonist atropine . To ensure comparable stimulation GLP-1 experimental condition decide perfuse meal directly duodenum . Comparisons : In ten healthy volunteer , interdigestive period follow 70 min duodenal perfusion mixed liquid meal ( 250 kcal ) . On four day random order , exendin ( 9-39 ) ( 300 pmol•kg-1•min-1 ) , atropine ( 5 µg•kg-1•h-1 ) , exendin ( 9-39 ) + atropine saline intravenously infuse . Antro-pyloro-duodenal perfusion manometry fundic motility ( electronic barostat ) assess parallel . Isobaric distension proximal stomach perform determine compliance .</detailed_description>
	<mesh_term>Atropine</mesh_term>
	<criteria>Male female ( postmenopausal , surgically sterile use doublebarrier method contraception ) healthy volunteer Age 1865 year Body mass index ( BMI ) &lt; 30 kg/m2 Must fast blood glucose 100 mg/dl screen study day Able provide write informed consent prior study participation Able communicate well investigator comply requirement study Diabetes mellitus Treatment systemic steroid thyroid hormone Patients history gastrointestinal surgery , e.g . partial bowel resection , partial gastric resection , etc . Participation clinical investigation within 4 week prior dose longer required local regulation . Donation loss 400 mL blood within 8 week prior dose . Significant illness within two week prior dose . Past medical history clinically significant electrocardiogram ( ECG ) abnormalities family history prolong QTinterval syndrome . History clinically significant drug allergy ; history atopic allergy ( asthma , urticaria , eczematous dermatitis ) . A known hypersensitivity study drug drug similar study drug . Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug may jeopardize subject case participation study . The investigator guide evidence following : history inflammatory bowel syndrome , gastritis , ulcer , gastrointestinal rectal bleed history major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection history clinical evidence pancreatic injury pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>GLP-1</keyword>
	<keyword>exendin ( 9-39 )</keyword>
	<keyword>atropine</keyword>
	<keyword>human</keyword>
	<keyword>motility</keyword>
</DOC>